Certara (CERT) has quickly moved into focus after reporting a second quarter net loss, reaffirming 2026 revenue guidance, and announcing executive changes and a larger share buyback that together reshape the risk picture for investors.

Over the past month Certara’s share price return of 13.39% and 90 day share price return of 28.84% point to building short term momentum, although the 1 year total shareholder return has declined 27.80% and the 5 year total shareholder return has declined 72.13%, showing a much weaker longer term picture.

If the mix of leadership changes, buybacks and earnings at Certara has caught your attention, it can be useful to compare it with other healthcare focused AI opportunities through the 42 healthcare AI stocks

Certara shares are trading close to analyst targets but still show a clear gap compared with some intrinsic value estimates. After the recent rebound and ongoing losses, it is worth asking where fair value really sits.

Most Popular Narrative: 8.7% Overvalued

Certara’s most followed narrative pegs fair value at $7.48 using an 8.77% discount rate, compared with the latest close at $8.13. This sets up a clear valuation gap for investors to unpack.

The upcoming commercial launch of Certara's next-generation, AI-enabled MIDD platform and CertaraIQ QSP software leverages advanced analytics and machine learning, providing differentiated capabilities that democratize access and increase the potential customer base, which should translate to higher recurring revenue and margin expansion through cloud-based SaaS models.

Read the complete narrative. Read the complete narrative.

Want to understand why this narrative still arrives at a premium price tag for Certara even after ongoing losses? The valuation hinges on a specific earnings path, a measured revenue ramp, and a margin profile more in line with mature software platforms. The assumptions behind those three levers are where the story really gets interesting.

Result: Fair Value of $7.48 (OVERVALUED)

However, Certara’s story could shift quickly if pharmaceutical spending tightens and its heavier R&D and acquisition costs do not translate into the expected software adoption.

Another View: DCF Points To Undervaluation

The analysts’ popular narrative suggests Certara looks 8.7% overvalued at $8.13, yet our DCF model points the other way. Using the SWS DCF model, Certara screens as undervalued by 9.9% against an estimated fair value of $9.02. Which set of assumptions feels more realistic to you?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Certara for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 50 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given the mixed signals around Certara, it makes sense to move quickly and review the underlying data yourself to see what stands out. To understand why some investors are still optimistic, you can take a closer look at the 2 key rewards for additional context.

Looking for more investment ideas beyond Certara?

Do not stop with Certara. Use the Simply Wall Street Screener to spot clear opportunities that match your style before others get there.

• Zero in on resilient companies by scanning 78 resilient stocks with low risk scores that may help you keep portfolio swings in check when markets get choppy.
• Hunt for potential bargains using the 50 high quality undervalued stocks to find stocks that combine quality fundamentals with prices that still look reasonable.
• Seek out future standouts with the screener containing 19 high quality undiscovered gems and see which under-the-radar stocks meet your preferred financial filters.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.